Quick Answer
PALVELLA THERAPEUTICS, INC. reported Cash and Equivalents of $57.98 million for fiscal year 2025.
PALVELLA THERAPEUTICS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $57.98M | -30.6% |
| 2024 | $83.60M | +1037.4% |
| 2023 | $7.35M | -81.0% |
| 2022 | $38.63M | -67.2% |
| 2021 | $117.76M | +67.2% |
| 2020 | $70.44M | +13.1% |
| 2019 | $62.26M | -16.8% |
| 2018 | $74.87M | +97.7% |
| 2017 | $37.88M | +29.0% |
| 2016 | $29.36M | +0.0% |
| 2015 | $29.35M | +58.9% |
| 2014 | $18.47M | +165766.5% |
| 2014 | $11.1K | -99.7% |
| 2013 | $3.69M | +70849.7% |
| 2013 | $5.2K | — |
| 2013 | $0.00 | -100.0% |
| 2012 | $6.33M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $63.57M | +228.3% | -9.7% |
| June 30, 2025 | $70.43M | +257.0% | -6.9% |
| March 31, 2025 | $75.63M | +296.3% | -9.5% |
| December 31, 2024 | $83.60M | +380.6% | +331.8% |
| September 30, 2024 | $19.36M | -41.1% | -1.9% |
| June 30, 2024 | $19.73M | -56.1% | +3.4% |
| March 31, 2024 | $19.08M | -52.0% | +9.7% |
| December 31, 2023 | $17.40M | -55.0% | -47.1% |
- PALVELLA THERAPEUTICS, INC. showed a decrease of -30.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, PALVELLA THERAPEUTICS, INC.’s cash and equivalents has grown by 816.4% (from $6.33 million to $57.98 million).
- The most recent figure is from PALVELLA THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: